The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

Related Posts

Addressing Complexities in Fontan Combined Heart-Liver Transplantation: A Collaborative Perspective

Lin J, Lubin L, Reardon L, Lluri G, Aboulhosn J, Cruz D, Vucicevic D, Wray C, Saab S, Venick R, Kaldas F, Si MS, Biniwale[...]

A phenotyping algorithm for classification of single ventricle physiology using electronic health records

Xu H, Renella P, Badiyan R, Hindosh ZR, Elisarraras FX, Zhu B, Satou GM, Husain M, Finn JP, Hsu W, Nguyen KL. A phenotyping algorithm[...]

Impact of Sudden Cardiac Arrest and Implantable Cardiac Defibrillator Shocks on Mental Health: Review and Management Guidance

Torbey E, Mena-Hurtado C, Jackson JL, Samaan Z, Sears SF, Pedersen SS, Lala A, Thachil R, Steiner J, Ilonze OJ, Jones D, Watson K, Price[...]